Skip to main content

Mesoblast Ltd

MESO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001345099

No open-market purchases or sales by Mesoblast Ltd insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $53.3M in total; no superinvestor holds it.

Other share classesMEOBF

Q4 2023 vs. Q3 2023

How the institutions holding Mesoblast Ltd changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of MESO: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders3531−4
Shares1.33M1.45M+123.0K (+9.3%)
Value$1.63M$1.59M−$37.5K (−2.3%)

New holders (7)

Institutions that held Mesoblast Ltd at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to MESO in Q4 2023
InstitutionSharesValue% of portfolio
FNY Investment Advisers, LLC20,000$22.0K0.02%
XTX Topco Ltd10,847$11.9K0.00%
Citadel Advisors LLC5,337$5.87K0.00%
UBS Group AG1,700$1.87K0.00%
GAMMA Investing LLC690$1.21K0.00%
Ronald Blue Trust, Inc.1,163$1.00K0.00%
Arlington Trust Co LLC172$1890.00%

Sold out (11)

Institutions that held Mesoblast Ltd at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of MESO in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Simplex Trading, LLC76,573$94.0K
Prosperity Wealth Management, Inc.64,150$78.9K
Virtu Financial LLC62,062$76.0K
Vident Advisory, LLC21,591$26.6K
Tobias Financial Advisors, Inc.20,000$24.6K
Ewa, LLC16,420$21.0K
Two Sigma Securities, LLC12,154$14.9K
Deltec Asset Management LLC12,000$14.8K
Quadrant Capital Group LLC3,236$3.98K
Signaturefd, LLC1,794$2.21K
Lindbrook Capital, LLC780$959